Franck Boccara
Inserm · 434 works · 9,475 citations · h-index 47
Top works
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
- Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms
- Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population
- Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies
- Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
- HIV and Coronary Heart Disease
- Beta-Blocker Interruption or Continuation after Myocardial Infarction
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study
- Acute Myopericarditis After Diphtheria, Tetanus, and Polio Vaccination
- Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
- HIV-associated lipodystrophy: from fat injury to premature aging
- HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals
- Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation
- Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis
- Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors